(Q24202427)

25 October 2023

5

Katja Komossa

Katja

Komossa

1 reference

25 October 2023

Christine Rummel-Kluge

series ordinal

4

object named as

Christine Rummel-Kluge

author given names

Christine

author last names

Rummel-Kluge

1 reference

25 October 2023

Laila Asmal

1

Laila

Asmal

1 reference

25 October 2023

Srnka J Flegar

series ordinal

2

author given names

Srnka J

author last names

Flegar

1 reference

25 October 2023

Jikun Wang

series ordinal

3

author given names

Jikun

author last names

Wang

1 reference

Cochrane Database of Systematic Reviews

25 October 2023

publication date

18 November 2013

0 references

published in

0 references

cites work

Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The impact of obesity on health care costs among persons with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Extrapyramidal side-effects of antipsychotics in a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Relationship of cognition and psychopathology to functional impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Results of phase 3 of the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

What CATIE found: results from the schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Subjective well-being and quality of life under atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Clinical experience with atypical antipsychotics in an acute inpatient unit: focus on quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Suicide and violent death among patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Assessment issues and the cost of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Aripiprazole for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Seroquel: electrophysiological profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Schizophrenia and employment - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Quetiapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

Metabolic findings from the CATIE trial and their relation to tolerability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

1 reference

7 January 2021

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006625.PUB3

7 January 2021